Injectable neural hydrogel as
ASCs
Hydrogel
PLGA
decellularized tissue
injectable
secretome
spinal cord injury
Journal
Regenerative engineering and translational medicine
ISSN: 2364-4133
Titre abrégé: Regen Eng Transl Med
Pays: Switzerland
ID NLM: 101669762
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
pmc-release:
01
09
2024
medline:
30
11
2023
pubmed:
30
11
2023
entrez:
30
11
2023
Statut:
ppublish
Résumé
This study demonstrated Rat-derived iPN hydrogel solutions were combined with a dextran-dye before subcutaneous injection into adult Sprague Dawley rats. After injection, an Gelation of iPN hydrogels was successful upon subcutaneous injection. When combined with iPN, a 10 kDa dextran-dye was reduced to 54% its initial signal at 24 hours, while PLGA-encapsulated dextran-dye in iPN was only reduced to 78% by 24 hours. Modified media stimulation resulted in changes in ASC phenotype and dramatic upregulation of VEGF secretion. The PLGA encapsulation protocol was adapted for use with temperature sensitive biomolecules, however, considerations must be made with loading efficiency for cell secretome as the maximum efficiency was 28%. The results of this study demonstrated successful injection and subsequent gelation of our iPN hydrogel formulation We developed an injectable decellularized tissue scaffold from rat peripheral nerve tissue (called iPN), a potential minimally invasive therapeutic meant to fill lesion spaces after injury. This study was the first demonstration of iPN delivery to a living animal. The iPN solution was injected subcutaneously in a rat and properly formed a gelled material upon entering the body. Our results showed that encapsulating biomolecules in an FDA-approved polymer (PLGA) slowed the release of biomolecules from the iPN, which could allow therapeutics more time around the scaffold to help repair native tissue. Lastly, we investigated one potential avenue for combining iPN with other regenerative cues obtained from adipose-derived stem cells. Future work must focus on optimal loading conditions and release profiles from the iPN hydrogels. Next steps will be applying iPN in various combination therapies for spinal cord injury. We will focus efforts on developing a pro-regenerative secretome that directly promotes neurite extension and neural cell infiltration into iPN scaffolds upon transplantation in spinal cord.
Identifiants
pubmed: 38031558
doi: 10.1007/s40883-022-00292-9
pmc: PMC10683944
mid: NIHMS1869718
doi:
Types de publication
Journal Article
Langues
eng
Pagination
424-430Subventions
Organisme : NINDS NIH HHS
ID : R21 NS111398
Pays : United States
Références
EMBO Mol Med. 2020 Mar 6;12(3):e11505
pubmed: 32090481
Biomaterials. 2018 Sep;177:176-185
pubmed: 29929081
J Cereb Blood Flow Metab. 2017 Jul;37(7):2320-2339
pubmed: 28378621
Stem Cells Dev. 2014 Apr 1;23(7):741-54
pubmed: 24124760
Biomed Pharmacother. 2019 Jun;114:108765
pubmed: 30921703
Tissue Eng Part A. 2013 Feb;19(3-4):368-79
pubmed: 22897220
PLoS One. 2011 Mar 14;6(3):e17899
pubmed: 21423756
Ann Biomed Eng. 2021 Dec;49(12):3401-3411
pubmed: 34704163
Prog Neurobiol. 2016 Jul;142:45-67
pubmed: 27166858
Cytokine Growth Factor Rev. 2019 Apr;46:1-9
pubmed: 30954374
Pharmaceuticals (Basel). 2021 Jan 11;14(1):
pubmed: 33440745
Stem Cell Res. 2016 May;16(3):622-34
pubmed: 27062357
Acta Biomater. 2012 Feb;8(2):511-8
pubmed: 22019759
Tissue Eng Part C Methods. 2020 Jan;26(1):23-36
pubmed: 31724493
Curr Stem Cell Res Ther. 2010 Jun;5(2):103-10
pubmed: 19941460
J Biomed Mater Res A. 2022 Mar;110(3):595-611
pubmed: 34590403
Stem Cells. 2009 Feb;27(2):478-88
pubmed: 19023032
Front Bioeng Biotechnol. 2020 Jan 21;7:469
pubmed: 32039177